Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Øynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Mælandsmo GM, Egeland EV, Prasmickaite L (2025)
Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer
Breast Cancer Res, 27 (1), 131
DOI 10.1186/s13058-025-02082-x, PubMed 40660361

Sorbye H, Hjortland GO, Vestermark LW, Ladekarl M, Svensson J, Sundlöv A, Janson ET, Garresori H, Hofsli E, Kersten C, Elvebakken H, Pfeiffer P, Morken S, Assmus J, Lothe IMB, Tabaksblat E, Knigge U, Couvelard A, Perren A, Langer SW (2025)
Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
Br J Cancer (in press)
DOI 10.1038/s41416-025-03095-1, PubMed 40659859

Panagopoulos I, Andersen K, Lloret I, Gorunova L, Lobmaier I (2025)
Novel FRMD6::PTH chimera in tumorous bone lesion carrying a t(4;11;14;12)(q35;p15;q22;q13)
Pathol Oncol Res, 31, 1612096
DOI 10.3389/pore.2025.1612096, PubMed 40641561